- authorisedTherapeutic exploratory (Phase II)
A Phase II, Randomized, Trial of Niraparib Versus Best Supportive Careas Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-line Platinum-containing Chemotherapy (MEET URO 12)
This study is looking at a new medicine called Zejula for people with a type of bladder cancer (urothelial cancer) that has spread. It's for patients who have already had chemotherapy and whose cancer hasn't gotten worse. We want to see if Zejula can help keep the cancer from growing for longer.
Italy - active not recruitingPHASE1, PHASE2
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
This study is testing a new drug, BT5528, for advanced cancers like ovarian, lung, and breast cancer. We want to find a safe dose, understand side effects, and see how well it works, sometimes given with another drug called nivolumab.
United States · Belgium · South Korea - recruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
United States · Canada · China - active not recruitingPHASE3
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
This study looks at new drug combinations for advanced bladder cancer that hasn't been treated before. It compares them to standard chemotherapy to see if they're safer and work better.
United States · Australia · Austria - ongoing, recruitingTherapeutic exploratory (Phase II)
C5701002/SGN22E-002 - A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
This study is looking at new ways to treat bladder cancer that has spread or come back. It's testing a new drug, Padcev, on its own or with other key cancer medicines to see how well they work and if they cause side effects.
France - active not recruitingPHASE3
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
This study is looking at how well two new drugs, enfortumab vedotin and pembrolizumab, work together to treat advanced bladder cancer that has spread. It compares them to standard chemotherapy treatments to see if they are a better option.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
This study looks at a new drug, erdafitinib, for advanced bladder cancer that has specific genetic changes. Researchers want to see if it works better than standard treatments like chemotherapy or pembrolizumab after previous treatments haven't helped enough.
United States · Argentina · Australia - active not recruitingPHASE3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This study offers continued access to treatments like Avelumab for people who were in earlier Pfizer studies and are still benefiting. It focuses on several cancers and ensures ongoing care and tracking of their health.
United States · Australia · Belgium - active not recruitingPHASE2
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
This study looks at a new drug, erdafitinib, for people with a type of bladder cancer called urothelial cancer that has spread or can't be removed by surgery. It aims to see how well it works and if it's safe, specifically for those with certain genetic changes in their cancer.
United States · Austria · Belgium - active not recruitingPHASE2
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
This study is testing new immune-based treatments for a type of bladder cancer that has spread. Researchers want to see if combinations of medicines like tobemstomig and tiragolumab are safe and work better than atezolizumab for people who can't have standard chemotherapy.
United States · Australia · Brazil - recruitingPHASE2, PHASE3
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
This study compares a new medicine, Iza-bren, with standard chemotherapy for advanced bladder cancer that has worsened after immunotherapy. It aims to see if Iza-bren is a better option for people who have already had certain treatments for their cancer.
United States · Argentina · Australia